Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | BMP1 | P13497 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5629775 | 0.90 | KMT2A (0.54) | KMT2AEPHX2CASP3BMP1TLR2 | |
| SCHEMBL5631609 | 0.90 | KMT2A (0.54) | KMT2AEPHX2CASP3BMP1TLR2 | |
| Hydrochloric Acid SCHEMBL5629771 | 0.89 | KMT2A (0.53) | KMT2AEPHX2CASP3BMP1TLR2 | |
| Hydrochloric Acid SCHEMBL5629777 | 0.89 | KMT2A (0.53) | KMT2AEPHX2CASP3BMP1TLR2 | |
| SCHEMBL31041102 | 0.88 | KMT2A (0.57) | KMT2AEPHX2CASP3BMP1TLR2 | |
| SCHEMBL8170342 | 0.88 | KMT2A (0.57) | KMT2AEPHX2CASP3BMP1TLR2 | |
| SCHEMBL16623132 | 0.88 | KMT2A (0.55) | KMT2AEPHX2CASP3PIN1BMP1 | |
| SCHEMBL3871611 | 0.88 | KMT2A (0.57) | KMT2AEPHX2CASP3BMP1TLR2 | |
| SCHEMBL14596379 | 0.87 | KMT2A (0.55) | KMT2AEPHX2CASP3PIN1FABP7 | |
| SCHEMBL17751746 | 0.86 | KMT2A (0.55) | KMT2AEPHX2CASP3BMP1FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365628-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365628-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | KMT2A 2835/4885EPHX2 4848/4885CASP3 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.